ClinicalTrials.gg
Not yet recruitingNCT07855601Updated Oct 2, 2026

Utilization of Residual Donor Tissue for Regrafting in Bullous Keratopathy After Corneal Transplantation

An interventional study of Endothelial keratoplasty using residual donor tissue in Bullous Keratopathy, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Postoperative endothelial cell loss following Descemet stripping endothelial keratoplasty (DSEK) remains a well-recognized clinical concern, with long-term follow-up demonstrating approximately 50% reduction in endothelial cell density by 5 years. Compounding this challenge, the critical shortage of corneal donors has severely limited the expansion of corneal transplantation programs in developing countries. In conventional penetrating keratoplasty, only the central 7-mm optical zone is typically harvested, whereas the peripheral donor tissue-whose endothelial cells are believed to exhibit superior viability-is routinely discarded.

To address these limitations, we describe the first-in-human use of three residual peripheral donor tissue segments, obtained after conventional keratoplasty, which were combined to perform corneal endothelial transplantation. This innovative approach substantially enhanced donor tissue utilization. Postoperatively, the patient achieved sustained corneal transparency with visual acuity improving from 20/500 to 20/50. Notably, the intersegmental gaps resolved progressively over time.

Extending this proof-of-concept case, we subsequently investigated the long-term stability and safety of residual donor tissue endothelial keratoplasty for bullous keratopathy, with comprehensive evaluation of postoperative visual acuity, intraocular pressure, corneal endothelial cell density, and refractive outcomes. This study aims to establish evidence-based support for the safety and efficacy of utilizing residual graft tissue in corneal endothelial transplantation.

02

Conditions studied

  • Bullous Keratopathy
03

In context

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 165 studies on the registry; 81 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with bullous keratopathy of various etiologies, with a corneal thickness of ≥650 μm, to medical treatment.
  • Aged ≥18 years.
  • The subject or their legally authorized guardian voluntarily consents to participate in this study and signs the form, with good compliance and willingness to attend follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Loss of vision in the fellow eye.
  • Corneal or ocular surface infection within 30 days prior to enrollment.
  • Severe dry eye, with Schirmer's test \< 5 mm.
  • Concurrent diseases that may affect the transplantation or prognosis, such as advanced glaucoma or retinal diseases.
  • Ocular surface .
  • Severe cicatrizing ocular disease; conjunctival scarring with fornix shortening.
  • Recent > 6.5%, or uncontrolled diabetes mellitus.
  • Severe impairment of vital organs, including the heart, liver, or kidneys.
  • Severe hematologic or endocrine disorders, or a history of such disorders.
  • Active disease.
  • Current signs of infection, including fever or ongoing antibiotic therapy.
  • Psychiatric disorders.
  • Pregnant or lactating women, or women planning pregnancy within 2 years.
  • Participation in other clinical studies or trials within 3 months.
  • Subjects who lack compliance with the study or the capacity to sign the form.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Postoperative corneal thickness

    To observe postoperative corneal thickness in patients with bullous keratopathy treated by endothelial keratoplasty using residual donor tissue following previous corneal transplantation.

    Procedure: Endothelial keratoplasty using residual donor tissue

Interventions

  • ProcedureEndothelial keratoplasty using residual donor tissue

    Endothelial keratoplasty using residual donor tissue from previous corneal transplantation

06

What researchers measure

Primary outcomes

  1. Corneal thickness

    Corneal thickness was measured preoperatively and postoperatively using an iVue OCT (OPTOVUE) or another OCT instrument, and the changes were compared.

    Time frame: Preoperatively and at postoperative day 1; at 1 and 2 weeks; and at 1, 2, 3, 6, and 12 months.

Secondary outcomes

  1. Best-corrected visual acuity (BCVA)

    Preoperative and postoperative visual acuity was assessed using the ETDRS chart.

    Time frame: Preoperatively and at postoperative day 1; at 1 and 2 weeks; and at 1, 2, 3, 6, and 12 months.

  2. Spherical equivalent (SE)

    Preoperative and postoperative SE was measured using a phoropter and an autorefractor, and differences before and after surgery as well as between the two groups were compared.

    Time frame: Preoperatively and at postoperative day 1; at 1 and 2 weeks; and at 1, 2, 3, 6, and 12 months.

  3. Corneal edema and opacity

    The degree of corneal edema and opacity was examined by slit-lamp microscopy.

    Time frame: Preoperatively and at postoperative day 1; at 1 and 2 weeks; and at 1, 2, 3, 6, and 12 months.

  4. Corneal endothelial cell count

    Postoperative corneal endothelial cell density was measured using laser confocal microscopy (Heidelberg Engineering, Germany) or a corneal endothelial specular microscope, and changes were compared.

    Time frame: At postoperative day 1 and at 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, and 12 months.

  5. Donor graft detachment

    Graft adhesion/apposition was evaluated by slit-lamp microscopy and OCT.

    Time frame: At postoperative day 1 and at 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, and 12 months.

  6. Intraocular pressure (IOP)

    Preoperative and postoperative IOP was measured using a non-contact tonometer.

    Time frame: Preoperatively and at 1, 3, 6, and 12 months postoperatively.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Apr 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Oct 17, 2026
Primary completionEst.
Apr 18, 2028
CompletionEst.
Oct 18, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855601
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 17, 2026 (estimated)
Primary completion
Apr 18, 2028 (estimated)
Completion
Oct 18, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Xiaojuan Dong
Contact
qingerdong@126.com
8613552338060

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion